Clinical trials: Consent of Patients
Hemorrhagic Shock
Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting
This study is designed to assess the survival benefit of administering PolyHeme to severely injured trauma patients in hemorrhagic shock beginning in the prehospital setting, where blood is not available, and continuing…
- Trial name
- NCT00076648
- Testing
- Poly SFH-P Injection
- Where
- 32 sites in United States
- Sponsor
- Northfield Laboratories
Recurrent Diffuse Pontine Gliomas
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
This is a phase 2, single-arm, multi-center study, with a safety review component, designed to evaluate the efficacy and safety of nimotuzumab in approximately 44 patients with recurrent diffuse intrinsic pontine glioma (DIPG)…
- Trial name
- NCT00600054
- Testing
- nimotuzumab (anti EGFR humanized monoclonal antibody)
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- YM BioSciences
Acute Myeloid Leukemia
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.
- Trial name
- NCT03790072
- Testing
- OmnImmune®
- Where
- Czechia
- Volunteers
- 10 people
- Sponsor
- TC Biopharm
Brain Injuries
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
- Trial name
- INTREPID2566 (NCT01366820)
- Testing
- NNZ-2566
- Where
- 6 sites in United States
- Volunteers
- 261 people
- Sponsor
- Neuren Pharmaceuticals Limited
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Acute Schizophrenia
A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
This is a randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), active-controlled…
- Trial name
- NCT00350467
- Testing
- ER OROS paliperidone and Olanzapine
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Diabetes Mellitus, Type 2
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability…
- Trial name
- CONSENT (NCT02252965)
- Testing
- Metformin IR, Metformin XR
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Merck KGaA, Darmstadt, Germany